VRBCF (Virbac) YoY EBITDA Growth: 36.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRBCF Virbac SA VRBCF
84 GF Score
Price $383.25
GF Value $351.25
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Virbac YoY EBITDA Growth?

Virbac VRBCF 84 YoY EBITDA Growth is 36.00% as of Dec. 2025. GuruFocus rates VRBCF with a GF Score™ of 84/100 and a GF Value™ of $351.25 (Fairly Valued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Virbac's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 36.00%.

Virbac's EBITDA per Share for the six months ended in Dec. 2025 was $17.72.

Virbac YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Virbac's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac YoY EBITDA Growth Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.11 3.14 3.81 15.81 16.06

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 27.01 6.18 -1.34 36.00
VRBCF
84GF Score
Virbac SA VRBCF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Virbac's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(40.069-34.525)/ | 34.525 |
=16.06 %

Virbac's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(17.722-13.031)/ | 13.031 |
=36.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 36.00% mean?
Virbac (VRBCF) has a YoY EBITDA Growth of 36.00% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Virbac and its competitors.
Is Virbac's YoY EBITDA Growth too high?
Virbac's current YoY EBITDA Growth is 36.00%. Overall, Virbac has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virbac's YoY EBITDA Growth compare to LLY and JNJ?
Virbac's YoY EBITDA Growth of 36.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Virbac and its competitors. Virbac's current YoY EBITDA Growth is 36.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (VRBCF) is currently considered Fairly Valued. The stock's GF Value™ is $351.25, compared to a current price of $383.25 — trading 9.1% above its estimated fair value. The current YoY EBITDA Growth is 36.00%. Virbac's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Virbac (VRBCF), the current YoY EBITDA Growth is 36.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (VRBCF) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be overvalued. The current stock price of $383.25 is trading 9.1% above its estimated GF Value™ of $351.25. GuruFocus considers Virbac to be Fairly Valued.

Key valuation signals for VRBCF:

  • YoY EBITDA Growth: 36.00%
  • GF Value™: $351.25 vs. price of $383.25 (9.1% above fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the VRBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
84GF Score

Get the complete analysis for VRBCF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$383.25
Price
$351.25
GF Value